Emilia Harding. Show Affiliations »
Abstract
Entities: Disease Gene
Mesh： See more » AdultAntineoplastic Combined Chemotherapy Protocols/therapeutic useBiomarkers, Tumor/metabolismBreast Neoplasms/drug therapyBreast Neoplasms/metabolismBreast Neoplasms/mortalityConfidence IntervalsDisease-Free SurvivalEstradiol/administration & dosageEstradiol/adverse effectsEstradiol/analogs & derivativesFemaleFulvestrantHumansMiddle AgedNeoplasm Invasiveness/pathologyPiperazines/administration & dosagePiperazines/adverse effectsPostmenopausePremenopauseProportional Hazards ModelsPyridines/administration & dosagePyridines/adverse effectsReceptor, ErbB-2/metabolismReceptors, Estrogen/metabolismSurvival RateTreatment Outcome
Substances： See more » Biomarkers, TumorPiperazinesPyridinesReceptors, EstrogenFulvestrantEstradiolReceptor, ErbB-2palbociclib
Year: 2015 PMID： 26062777 DOI： 10.1016/S1470-2045(15)00032-7
Source DB: PubMed Journal: Lancet Oncol ISSN： 1470-2045 Impact factor: 41.316